SC
SION

Stempoint Capital’s Sionna Therapeutics SION Stock Holding History

Stempoint Capital’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.61M Buy
59,426
+22,886
+63% +$916K 0.45% 58
2026
Q1 		$1.46M Buy
+36,540
New +$1.39M 0.28% 58
2025
Q2 		– Sell
-60,000
Closed -$628K – 82
2025
Q1 		$628K Buy
+60,000
New +$980K 0.2% 51

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Stempoint Capital's SION Position: Q2 2026 in Review

Stempoint Capital increased its Sionna Therapeutics (SION) stake by 63% in Q2 2026, buying an estimated $916K and bringing the position to 59,426 shares worth $2.61M. The position accounts for 0.45% of the portfolio, ranked #58.

Stempoint Capital first reported a position in SION in Q1 2025 and has held it in 3 quarters since. 147 funds tracked by Wall St. Rank hold SION as of Q2 2026.

  • Stempoint Capital held 59,426 shares of Sionna Therapeutics worth $2.61M as of Q2 2026.
  • Stempoint Capital bought 22,886 Sionna Therapeutics shares in Q2 2026, an estimated $916K.
  • Sionna Therapeutics made up 0.45% of Stempoint Capital's portfolio in Q2 2026, its #58 holding.
  • Stempoint Capital first reported a position in Sionna Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • 147 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.